Viridian Therapeutics, Inc.

VRDN

NASDAQHealthcareBiotechnology

在 GoAI 中打开

常规交易时段

US$24.15

−US$0.14 · -0.58%

8月24日 10:29 ET

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

53/ 100

GoAI评分

Hold

Wait — insufficient conviction to act

估值

Undervalued

动量

Neutral

情绪

Bullish

风险韧性

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Stephen F. Mahoney
上市以来: 2014年6月18日
雇员: 252

市场位置

日内区间

当前US$24.15，

US$24.06US$24.41

52周区间

当前US$24.15，

US$13.18US$34.29

开盘价: US$24.35
前收盘价: US$24.29
成交量: 19.38万; 0.08× 平均值
平均成交量: 230.85万; 日均成交量
市值: 27.36亿 USD
贝塔: 0.94; 市场参考 1
50天平均值: US$19.7476; 高于平均水平+22.29%
200天平均值: US$23.9769; 高于平均水平+0.72%

财务数据

财务快照

估值与收益率

企业价值: 24.77亿 USD
市盈率（TTM）: -6.84×
市净率（TTM）: 3.94×
市销率（TTM）: 38.47×
EV/EBITDA: -7.35×
盈利收益率: -12.98%
自由现金流收益率: -10.49%
股息率: 0.00%

盈利能力和效率

毛利率: 99.38%
营业利润率: -569.68%
净利润率: -544.06%
净资产收益率: -47.44%
资产收益率: -38.09%
投入资本回报率: -43.81%

财务健康

负债权益比: 0.37×
流动比率: 12.65×

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$37.25

上涨空间 54.24%

过去 12 个月12个月预测

价格历史记录不可用

最高：US$45.00平均的：US$37.25最低：US$26.00

VRDN 消息

defenseworld.net2026年8月24日

Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN

Deutsche Bank AG bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 482,875 shares of the…

阅读源码

globenewswire.com2026年8月6日

Viridian Reports Continuation of Massive Sulphides at Kraken Main; First Assays Pending

OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond drill holes completed as part of Viridian Metals Inc.'s (CSE: VRDN) (OTCQB: VIRMF) 2026 drill program at the Kraken project…

阅读源码

gurufocus.com2026年8月6日

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines

阅读源码

businesswire.com2026年8月6日

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare…

阅读源码

defenseworld.net2026年8月3日

Viridian Therapeutics (NASDAQ:VRDN) and Zai Lab (NASDAQ:ZLAB) Financial Review

Zai Lab (NASDAQ: ZLAB - Get Free Report) and Viridian Therapeutics (NASDAQ: VRDN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the…

阅读源码

zacks.com2026年7月1日

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.

阅读源码